Tubulis enters into collaboration with Gilead Sciences
The agreement, valued at up to $415 million, combines Gilead’s long-standing expertise with Tubulis’ innovative technology to advance ADC treatment for solid tumors.
OCCIDENT
We invest in deep tech start-ups with a focus on spin-offs originating from
scientific research. What motivates us is having a real impact and enabling
concrete solutions for different challenges facing society today.
scientific research. What motivates us is having a real impact and enabling
concrete solutions for different challenges facing society today.
As a venture capital investor, we support start-ups from the seed stage onwards and enable founding teams to achieve outstanding results. With a strong entrepreneurial mindset, we invest our own money and make decisions based on sustainable potential for success.
Portfolio
Co-operation with the founding teams of our portfolio companies motivates and inspires us every day. We are energized by their passion and drive, and the often very intense exchange spurs us on to tackle challenges together.
Want to learn more about OCCIDENT?
OCCIDENT in numbers
Portfolio News
Thermosome presents encouraging first clinical data
Phase I Trial data show safety and potential efficacy in heavily pre-treated soft tissue sarcoma patients. In 4 out of 6 patients, the disease remained stable per RECIST.
ReCatalyst is celebrating major achievements
Our portfolio company ReCatalyst reaches significant product milestones and signs a memorandum of understanding with a Membrane Electrode Assembly producer.
The Science Investor.
The OCCIDENT Team
Curious, perceptive, grounded and courageous, yet also humorous and team-oriented – that is the OCCIDENT team. As experts in our field, we know exactly what we are doing.
